LVAD Survival Better When Combined with ICD
By HospiMedica International staff writers Posted on 19 Jul 2016 |

Image: According to a new study, patient survival with a left ventricular assist device (LVAD) is better when an implantable cardioverter defibrillator (ICD) is also present (Photo courtesy of BCM).
Researchers at the Minneapolis Veterans Affairs (VA) Health Care System (MN, USA) conducted a systematic review and meta-analysis of studies published in PubMed and OVID databases from January 2000 through October 2015 in order to evaluate the impact of ICDs on mortality in patients with LVADs. In all, six relevant studies were identified, which included 937 patients (mean age 53 years, 80% male). A continuous-flow LVAD was present in 39% of the patients, and an ICD was present in 38%.
The results showed that among LVAD patients, all-cause mortality rates were 16% with an ICD, versus 32% without one, over a mean follow-up period of 7 months. Patients with newer, continuous flow LVADs showed a similar, but non-significant trend for better survival with an ICD (14% versus 25%, respectively). The authors acknowledged that they failed to totally exclude patients with biventricular assist devices (17%) and right ventricular assist devices (4%). The study was published in the July 2016 issue of JACC: Heart Failure.
“The evidence supporting ICD use in patients with LVADs is limited to a few, relatively small studies. Current practice guidelines supporting ICD use in LVAD patients are therefore predominantly based on expert consensus and observational studies,” wrote lead author Kairav Vakil, MD, and colleagues, adding that, “this cohort was enriched with patients that received an LVAD as bridge-to-transplantation. As such, these results cannot be generalized to patients receiving destination therapy LVADs, who are known to be relatively sicker than those awaiting transplantation.”
An LVAD is intended to complement a weakened heart by providing circulatory support. Surgically implanted in proximity to the heart, one end is attached to the left ventricle, while the other is attached to the aorta. Blood flows from the ventricles into the pump and is then ejected out of the device and into the aorta. Although the mechanism of survival benefit from ICDs in LVAD patients remains unclear, a possible explanation is that it may contribute to a reduction in harmful effects of ventricular arrhythmias on right ventricular function, thereby leading to reduction of heart failure deaths.
Related Links:
Minneapolis Veterans Affairs
The results showed that among LVAD patients, all-cause mortality rates were 16% with an ICD, versus 32% without one, over a mean follow-up period of 7 months. Patients with newer, continuous flow LVADs showed a similar, but non-significant trend for better survival with an ICD (14% versus 25%, respectively). The authors acknowledged that they failed to totally exclude patients with biventricular assist devices (17%) and right ventricular assist devices (4%). The study was published in the July 2016 issue of JACC: Heart Failure.
“The evidence supporting ICD use in patients with LVADs is limited to a few, relatively small studies. Current practice guidelines supporting ICD use in LVAD patients are therefore predominantly based on expert consensus and observational studies,” wrote lead author Kairav Vakil, MD, and colleagues, adding that, “this cohort was enriched with patients that received an LVAD as bridge-to-transplantation. As such, these results cannot be generalized to patients receiving destination therapy LVADs, who are known to be relatively sicker than those awaiting transplantation.”
An LVAD is intended to complement a weakened heart by providing circulatory support. Surgically implanted in proximity to the heart, one end is attached to the left ventricle, while the other is attached to the aorta. Blood flows from the ventricles into the pump and is then ejected out of the device and into the aorta. Although the mechanism of survival benefit from ICDs in LVAD patients remains unclear, a possible explanation is that it may contribute to a reduction in harmful effects of ventricular arrhythmias on right ventricular function, thereby leading to reduction of heart failure deaths.
Related Links:
Minneapolis Veterans Affairs
Latest Critical Care News
- Cuff-Free Blood Pressure Monitoring Device to Improve Early Detection and Management of Hypertension
- New Understanding of Barrett’s Esophagus Formation to Enable Earlier Intervention and Diagnosis
- 3D Printed Functional Human Islets Could Transform Type 1 Diabetes Treatment
- AI Model Predicts ICU mortality in Heart Failure Patients
- Smart Capsule Offers Real-Time Profiling Across GI Tract
- Ultra-Thin Implant Helps Patients with Spinal Cord Injury Recover Lost Functions
- Portable Cell Therapy Device to Enable Rapid On-Demand Modification of RBCs at POC
- Monitoring Airborne Fungal Spores Could Help Predict COVID-19 & Flu Surges
- New System Measures Blood Sodium Without Needles
- Sleep Data from Wearable Device May Help Predict Preterm Birth
- AI Tool Interprets Echocardiograms in Minutes
- Electrochemical Catheter Hub Prevents Bloodstream Infections
- Noninvasive Double Microbubble Delivery Approach Marks Breakthrough in Brain Cancer Treatment
- Self-Healing Skin-Like Material to Find Applications in Health Monitoring, Surgery and Implants
- Highly-Sensitive Electronic Skin Allows Robots to Feel Heat, Pain and Pressure
- AI-Powered Wearable Sensor Predicts Labor Onset in Pregnant Women
Channels
Surgical Techniques
view channel
Neuroform Atlas Stent-Assisted Coiling Found Effective Even in Smaller Arteries
Aneurysms, especially when located in the brain, can be life-threatening if not treated effectively. Intracranial aneurysms, caused by the dilation of blood vessels due to weaknesses in the vessel wall,... Read more
New Surgical Technique Safely Removes Giant Nerve Tumors
Giant plexiform neurofibromas (PNF) are benign tumors commonly associated with neurofibromatosis Type 1 (NF1), a genetic disorder affecting approximately 1 in 3,000 live births. These tumors, which occur... Read morePatient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Smartwatches Could Detect Congestive Heart Failure
Diagnosing congestive heart failure (CHF) typically requires expensive and time-consuming imaging techniques like echocardiography, also known as cardiac ultrasound. Previously, detecting CHF by analyzing... Read moreBusiness
view channel
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more